Structure-based drug design to augment hit discovery.

Several technology-based strategies have been developed to address the significance of the two phases of drug discovery: hit identification and lead identification. Structure-based drug design (SBDD), a method that depends on possessing the knowledge of 3D structures of biological targets, is growing swiftly with the development of new technologies for searching potential ways to combat disease. The past decade has evidenced a threefold increase in the amount of software and tools in the online repositories. Herein, we review the in silico strategies and modules applied at the level of hit identification and confer the different challenges with possible solutions in enhancing the success rate of the 'hit-to-lead' phase that could eventually help the progress of SBDD in the drug discovery arena.

[1]  Luhua Lai,et al.  Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. , 2009, Journal of medicinal chemistry.

[2]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[3]  B. Shoichet,et al.  Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.

[4]  T. Schwede,et al.  Protein structure homology modeling using SWISS-MODEL workspace , 2008, Nature Protocols.

[5]  Jie Liang,et al.  CASTp: Computed Atlas of Surface Topography of proteins , 2003, Nucleic Acids Res..

[6]  Donald B. Boyd,et al.  How Computational Chemistry Became Important in the Pharmaceutical Industry , 2007 .

[7]  Leland J. Gershell,et al.  A brief history of novel drug discovery technologies , 2003, Nature Reviews Drug Discovery.

[8]  Liao Jie-Lou Jeffrey and Andrews C. Robert,et al.  Targeting protein multiple conformations: a structure-based strategy for kinase drug design. , 2007 .

[9]  M. Schroeder,et al.  LIGSITEcsc: predicting ligand binding sites using the Connolly surface and degree of conservation , 2006, BMC Structural Biology.

[10]  Caitlin Smith,et al.  Drug target identification: A question of biology , 2004, Nature.

[11]  Alexander Hillisch,et al.  Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. , 2006, Drug discovery today.

[12]  Yvonne C. Martin,et al.  Let’s not forget tautomers , 2009, J. Comput. Aided Mol. Des..

[13]  A. Anderson.  The process of structure-based drug design. , 2003, Chemistry & biology.

[14]  Paul A. Bartlett,et al.  CAVEAT: A program to facilitate the design of organic molecules , 1994, J. Comput. Aided Mol. Des..

[15]  Thomas E. Exner,et al.  Influence of Protonation, Tautomeric, and Stereoisomeric States on Protein-Ligand Docking Results , 2009, J. Chem. Inf. Model..

[16]  Andrew R. Leach,et al.  Structure-based Drug Discovery , 2007 .

[17]  Ingo Muegge,et al.  Advances in virtual screening , 2006, Drug Discovery Today: Technologies.

[18]  Claudio N. Cavasotto,et al.  High-throughput and in silico screenings in drug discovery , 2009, Expert opinion on drug discovery.

[19]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[20]  Sean Ekins,et al.  Computer Applications in Pharmaceutical Research and Development , 2008 .

[21]  B Fischer,et al.  Receptor flexibility for large-scale in silico ligand screens: chances and challenges. , 2008, Methods in molecular biology.

[22]  David B. Searls,et al.  Data integration: challenges for drug discovery , 2005, Nature Reviews Drug Discovery.

[23]  György M Keseru,et al.  Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.

[24]  Dennis M. Krüger,et al.  Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.

[25]  Mohane Selvaraj Coumar,et al.  Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity. , 2009, Journal of medicinal chemistry.

[26]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[27]  Richard M. Jackson,et al.  Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites , 2005, Bioinform..

[28]  Victor Guallar,et al.  Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (QM/MM) approach , 2005, J. Comput. Chem..

[29]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[30]  Valerie J. Gillet,et al.  SPROUT: Recent developments in the de novo design of molecules , 1994, J. Chem. Inf. Comput. Sci..

[31]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[32]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[33]  Brett A Tounge,et al.  Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.

[34]  T dePaulis.  Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. , 2007 .

[35]  Andrea Scozzafava,et al.  Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. , 2009, Bioorganic & medicinal chemistry.

[36]  Pedro Alexandrino Fernandes,et al.  Protein–ligand docking: Current status and future challenges , 2006, Proteins.

[37]  Gareth Thomas,et al.  Medicinal Chemistry: An Introduction , 2000 .

[38]  Antony J. Williams,et al.  A perspective of publicly accessible/open-access chemistry databases. , 2008, Drug discovery today.

[39]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[40]  Keehyoung Joo,et al.  Improving physical realism, stereochemistry, and side‐chain accuracy in homology modeling: Four approaches that performed well in CASP8 , 2009, Proteins.

[41]  Joo Chuan Tong,et al.  Recent advances in computer-aided drug design , 2009, Briefings Bioinform..

[42]  Alexandre M J J Bonvin,et al.  Are scoring functions in protein-protein docking ready to predict interactomes? Clues from a novel binding affinity benchmark. , 2010, Journal of proteome research.

[43]  Corey Nislow,et al.  Recent advances and method development for drug target identification. , 2010, Trends in pharmacological sciences.

[44]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[45]  R M Stroud,et al.  Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity. , 1996, Structure.

[46]  G. Marshall.  Computer-aided drug design. , 1987, Annual review of pharmacology and toxicology.

[47]  Pierre Tufféry,et al.  wwLigCSRre: a 3D ligand-based server for hit identification and optimization , 2009, Nucleic Acids Res..

[48]  J. Gready,et al.  Combining docking and molecular dynamic simulations in drug design , 2006, Medicinal research reviews.

[49]  Yuval Inbar,et al.  Protein structure modelling and evaluation based on a 4-distance description of side-chain interactions , 2010, BMC Bioinformatics.

[50]  Takeshi Kobayashi,et al.  Novel strategy for protein exploration: high-throughput screening assisted with fuzzy neural network. , 2005, Journal of molecular biology.

[51]  D. E. Clark.  What has computer-aided molecular design ever done for drug discovery? , 2006, Expert opinion on drug discovery.

[52]  Feng Chen,et al.  Using bioinformatics techniques for gene identification in drug discovery and development. , 2008, Current drug metabolism.

[53]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[54]  C. Sotriffer,et al.  Docking compared to 3D-pharmacophores: the scoring function challenge , 2010 .

[55]  Xiaoqin Zou,et al.  Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. , 2010, Physical chemistry chemical physics : PCCP.

[56]  Marianne A Grant,et al.  Protein structure prediction in structure-based ligand design and virtual screening. , 2009, Combinatorial chemistry & high throughput screening.

[57]  Weiliang Zhu,et al.  New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery , 2006, Drug Discovery Today: Technologies.

[58]  Robert Alan Goodnow,et al.  Hit and lead identification: Integrated technology-based approaches , 2006 .